Mangoceuticals Inc. (NASDAQ:MGRX) shares are surging on Monday. However, there is no news to justify the movement.The momentum could be due to last week’s announcement of a lawsuit seeking damages exceeding 73 million dollars against its former technology partner, Clarity Ventures.Lawsuit DetailsThe lawsuit, filed in Texas state court, alleges that Clarity failed to deliver a fully functional, HIPAA-compliant enterprise resource planning and eCommerce platform, which was crucial for Mangoceuticals’ operatio ...

Dallas, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals,” the “Company,” or “MangoRx”), a company focused on developing, marketing, and selling health and wellness products through a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that it has filed a civil lawsuit against Clarity Ventures, Inc., its former technology consulting and software development firm (“Clarity”). The lawsuit, filed in Texas state court, seeks damages ...

Dallas, TX, March 06, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions and its partner IntraMont Technologies, Inc. today announced the filing of a Patent Cooperation Treaty (PCT) international application (P-641039-PC) on February 26, 2026, to secure broad global patent protect ...

Dallas, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, today announced new data from its proprietary antiviral compound MGX-0024. A technical report issued by partner IntraMont Technologies in late 2025, combined with the final signed report from the ICAR-Nationa ...

Here’s what investors need to know.Mangoceuticals shares are powering higher. Why is MGRX stock surging?TRT Sales Surge 336%Since launching in mid-December, month-over-month sales for the injectable TRT program have climbed 336%, while customer acquisition costs have fallen 54%, the company said in an update. Management expects TRT to be the primary growth driver as MangoRx expands both injectable and oral options, including its PRIME capsule, powered by Kyzatrex.Telehealth Platform Targets Growing TRT Mark ...

Core Insights - Mangoceuticals, Inc. has experienced a significant increase in stock price following the announcement of initial success for its injectable Testosterone Replacement Therapy (TRT) program [1][4] Group 1: Sales Performance - Month-over-month sales of the injectable TRT program have surged by 336% since its launch in mid-December [2] - The company has achieved a 54% reduction in customer acquisition costs during the same period [2] Group 2: Strategic Focus - The company anticipates that TRT will be its primary growth driver moving forward, with ongoing investments in both injectable and oral formulations [3] - CEO Jacob Cohen emphasized that initial customer demand and sales acceleration validate the company's approach to men's hormone health, reinforcing TRT as a key strategic focus [3]

Core Insights - Mangoceuticals, Inc. has reported a month-over-month sales increase of 336% for its newly launched all-inclusive injectable Testosterone Replacement Therapy (TRT) program, which is priced at $99 per month [1][2] - The company has successfully reduced its customer acquisition costs by 54% during the same period, indicating improved marketing efficiency [2] - The global testosterone replacement therapy market is valued at approximately $2.11 billion to $2.2 billion in 2025, with a projected compound annual growth rate (CAGR) of around 3.9% [4] Company Developments - The strong sales momentum for the TRT program reflects growing demand for convenient and effective TRT options, supported by the company's telehealth platform [3] - MangoRx aims to expand its TRT offerings, including both injectable and oral formulations, to capture a larger market share in this high-demand segment [3] - The company is committed to evolving its telehealth platform to provide a broader range of men's health and wellness solutions beyond single treatments [5] Strategic Focus - The CEO of Mangoceuticals emphasized the importance of their innovative approach to men's hormone health and the strategic focus on TRT as a key growth driver [4] - The company plans to build a more comprehensive platform that delivers a wider array of wellness solutions, which is expected to strengthen its operational and financial foundation [4]

As filed with the Securities and Exchange Commission on January 23, 2026 Registration No. 333-292711 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to UNDER THE SECURITIES ACT OF 1933 Mangoceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) FORM S-1 REGISTRATION STATEMENT 17130 N. Dallas Parkway, Suite 240 Dallas, Texas 75248 (214 ...

As filed with the Securities and Exchange Commission on January 13, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Mangoceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Texas 8099 87-3841292 (State or other jurisdiction of (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 17130 N. Dallas Parkway, Suite 240 Dallas, Texas 7524 ...

Market Overview - U.S. stocks traded higher, with the Nasdaq Composite gaining over 1% on Friday, while the Dow rose 0.55% to 48,216.43, and the S&P 500 increased by 0.83% to 6,830.85 [1] - Information technology shares rose by 1.6%, while consumer staples stocks fell by 0.4% [1] Company Performance - Nike Inc. shares fell around 10% despite reporting second-quarter revenue of $12.43 billion, exceeding analyst estimates of $12.22 billion, and earnings of 53 cents per share, surpassing estimates of 38 cents per share. The decline in gross margins for the second consecutive quarter contributed to the stock's drop [2] Commodity Market - Oil prices increased by 0.9% to $56.66, gold rose by 0.4% to $4,381.60, silver surged 3.4% to $67.415, and copper gained 1.1% to $5.4955 [5] European Market - European shares were higher, with the eurozone's STOXX 600 gaining 0.37%, Spain's IBEX 35 Index rising 0.22%, London's FTSE 100 up by 0.61%, Germany's DAX 40 increasing by 0.37%, and France's CAC 40 gaining 0.01% [6] Asian Market - Asian markets closed higher, with Japan's Nikkei 225 gaining 1.03%, Hong Kong's Hang Seng up by 0.75%, China's Shanghai Composite rising 0.36%, and India's BSE Sensex increasing by 0.53% [7] Notable Stock Movements - Autozi Internet Technology shares surged 54% to $2.34 after announcing a $90 million initial equity investment [9] - Amicus Therapeutics shares rose 31% to $14.20 following the announcement of its acquisition by BioMarin for a total equity value of about $4.8 billion, with BioMarin shares up 19% to $61.88 [9] - Lamb Weston Holdings shares dropped 25% to $44.70 after second-quarter results, while BlackBerry shares fell 10% to $3.90 following third-quarter results [9] - Mangoceuticals Inc. shares declined 45% to $0.72 after announcing a $100 million Solana-focused digital asset treasury strategy [9]